[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Doering et al., 2015 - Google Patents

Melanocortin antagonist tetrapeptides with minimal agonist activity at the mouse melanocortin-3 receptor

Doering et al., 2015

View HTML
Document ID
12322346741871939422
Author
Doering S
Todorovic A
Haskell-Luevano C
Publication year
Publication venue
ACS medicinal chemistry letters

External Links

Snippet

The melanocortin system regulates many important functions in the body. There are five melanocortin G protein-coupled receptor subtypes known to date. Herein, we report a structure–activity relationship (SAR) study of a tetrapeptide lead discovered through a …
Continue reading at pubs.acs.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Haskell-Luevano et al. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants
Doering et al. Melanocortin antagonist tetrapeptides with minimal agonist activity at the mouse melanocortin-3 receptor
Tota et al. Molecular interaction of Agouti protein and Agouti-related protein with human melanocortin receptors
Pogozheva et al. Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists
Grieco et al. D-amino acid scan of γ-melanocyte-stimulating hormone: Importance of Trp8 on human MC3 receptor selectivity
Wilczynski et al. Identification of putative agouti-related protein (87− 132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands
Holder et al. Structure− activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 at the mouse melanocortin receptors: part 2 modifications at the Phe position
Haskell-Luevano et al. Characterization of melanocortin NDP-MSH agonist peptide fragments at the mouse central and peripheral melanocortin receptors
Testa et al. 1, 4-disubstituted-[1, 2, 3] triazolyl-containing analogues of MT-II: design, synthesis, conformational analysis, and biological activity
Singh et al. Synthesis and pharmacology of α/β3-peptides based on the melanocortin agonist Ac-His-DPhe-Arg-Trp-NH2 sequence
Falls et al. Insights into the allosteric mechanism of setmelanotide (RM-493) as a potent and first-in-class melanocortin-4 receptor (MC4R) agonist to treat rare genetic disorders of obesity through an in silico approach
Ericson et al. Discovery of a β-hairpin octapeptide, c [Pro-Arg-Phe-Phe-Dap-Ala-Phe-DPro], mimetic of agouti-related protein (87–132)[AGRP (87–132)] with equipotent mouse melanocortin-4 receptor (mMC4R) antagonist pharmacology
Xiang et al. Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist
Chai et al. Receptor− Antagonist Interactions in the Complexes of Agouti and Agouti-Related Protein with Human Melanocortin 1 and 4 Receptors
Ericson et al. Structure–Activity Relationship Studies on a Macrocyclic Agouti-Related Protein (AGRP) Scaffold Reveal Agouti Signaling Protein (ASP) Residue Substitutions Maintain Melanocortin-4 Receptor Antagonist Potency and Result in Inverse Agonist Pharmacology at the Melanocortin-5 Receptor
Palmer et al. Click-chemistry-mediated synthesis of selective melanocortin receptor 4 agonists
Ericson et al. A macrocyclic agouti-related protein/[Nle4, DPhe7] α-melanocyte stimulating hormone chimeric scaffold produces subnanomolar melanocortin receptor ligands
Zhou et al. Design of MC1R selective γ-MSH analogues with canonical amino acids leads to potency and pigmentation
Fleming et al. Structure–Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c [Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice
Xiang et al. Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms
Doering et al. Discovery of mixed pharmacology melanocortin-3 agonists and melanocortin-4 receptor tetrapeptide antagonist compounds (TACOs) based on the sequence Ac-Xaa1-Arg-(pI) DPhe-Xaa4-NH2
Fleming et al. Synergistic multiresidue substitutions of a macrocyclic c [Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] agouti-related protein (AGRP) scaffold yield potent and> 600-fold MC4R versus MC3R selective melanocortin receptor antagonists
Chen et al. Molecular characterization of human melanocortin-3 receptor ligand− receptor interaction
Cai et al. Systematic backbone conformational constraints on a cyclic melanotropin ligand leads to highly selective ligands for multiple melanocortin receptors
Joseph et al. The 1, 4-benzodiazepine-2, 5-dione small molecule template results in melanocortin receptor agonists with nanomolar potencies